Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility Study of a Single Priming Dose of NeisVac-C in Infants
2010-019383-36Phase 3Completed
- Sponsor
- Baxter International Inc.
- Start
- Jun 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Meningococcal group C polysaccharide conjugate vaccine in meningococcal disease and invasive meningococcal disease (IMD) (2 arms), sponsored by Baxter International Inc. Primary endpoints: Immunogenicity co-primary endpoints and Safety (local and systemic reactions). Started Jun 2010; status: completed.
02
Drugs
Meningococcal group C polysaccharide conjugate vaccine
03
Conditions
meningococcal diseaseinvasive meningococcal disease (IMD)
Beyond the preview
Go deeper on 2010-019383-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019383-36.